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Osteosarcoma is the most common type of bone cancer in children and adolescents.
Impaired differentiation of osteoblast cells is a distinguishing feature of this aggressive
disease. As improvements in survival outcomes have largely plateaued, better
understanding of the bone differentiation program may provide new treatment
approaches. The miRNA cluster miR-23a∼27a∼24-2, particularly miR-23a, has been
shown to interact with genes important for bone development. However, global changes
in gene expression associated with functional gain of this cluster have not been fully
explored. To better understand the relationship between miR-23a expression and bone
cell differentiation, we carried out a large-scale gene expression analysis in HOS cells.
Experimental results demonstrate that over-expression of miR-23a delays differentiation
in this system. Downstream bioinformatic analysis identified miR-23a target gene
connexin-43 (Cx43/GJA1), a mediator of intercellular signaling critical to osteoblast
development, as acutely affected by miR-23a levels. Connexin-43 is up-regulated in the
course of HOS cell differentiation and is down-regulated in cells transfectedwithmiR-23a.
Analysis of gene expression data, housed at Gene Expression Omnibus, reveals that
Cx43 is consistently up-regulated during osteoblast differentiation. Suppression of Cx43
mRNA by miR-23a was confirmed in vitro using a luciferase reporter assay. This work
demonstrates novel interactions between microRNA expression, intercellular signaling
and bone differentiation in osteosarcoma.
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1. Introduction
Osteosarcoma is the most common primary bone malignancy and occurs most frequently in
adolescents (Mirabello et al., 2009). Osteosarcoma tumors most often arise in the long bones
of the skeleton, with more than half presenting around the knee (Broadhead et al., 2011),
and is less common in axial skeleton (Martin et al., 2012). At diagnosis, 20% of osteosarcoma
patients present with lung metastases with an additional 40% developing metastases at later stage
(Martin et al., 2012). Survival rates for localized osteosarcoma are at 60–70% (Longhi et al.,
2006; Mirabello et al., 2009), while the 5-year survival for osteosarcoma patients with metastases
is 20% (PosthumaDeBoer et al., 2011). Despite intense research efforts, the survival rates for
osteosarcoma have remained essentially unchanged for over two decades (Longhi et al., 2006;
Mirabello et al., 2009). Contributing to the challenge of understanding and ultimately developing
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effective treatments for osteosarcoma is its complex karyotype
and high level of chromosomal instability (Helman and Meltzer,
2003). With the increasing understanding of osteosarcoma
biology, perturbation of cell differentiation is often regarded
as aspect of this disease (Thomas and Kansara, 2006; Tang
et al., 2008). Therefore, it is possible that the path toward
developing new treatment approaches for osteosarcoma lies
through an improved understanding of the dysregulation of the
bone differentiation program in this devastating disease.
Discovery of small (about 22nt in length) non-coding RNA
species, termed microRNAs (miRNAs), has, in many ways,
revolutionized the understanding of gene expression regulation.
It is now recognized, for instance, that miRNAs contribute
to many biological processes (Ambros, 2004) and that their
expression patterns can be used to classify cancers (Lu et al.,
2005; Bloomston et al., 2007), suggesting that miRNAs play the
roles similar to tumor suppressors and oncogenes (Dalmay and
Edwards, 2006; Esquela-Kerscher and Slack, 2006). MicroRNAs
play an integral role in controlling cell differentiation by
suppressing genes that maintain plasticity (Yi et al., 2008), or by
suppressing genes that inhibit cell-lineage commitment (Li et al.,
2008) or through a combination of the two (Forrest et al., 2010).
miRNAs play a paramount role in bone differentiation
(Sugatani and Hruska, 2007; Kobayashi et al., 2008; Wang et al.,
2008; Inose et al., 2009; Hassan et al., 2012). Recent studies
identified miRNA biomarkers relevant to therapy response and
identification of therapeutic targets (Lulla et al., 2011; Maire et al.,
2011; Jones et al., 2012; Cai et al., 2013). Much attention has been
devoted to the role of miR-23a in bone differentiation, primarily
via its targeting (both direct and indirect) of transcription factors
essential to osteoblastogenesis such as TRPS1, RUNX2, and
SATB2 (Hassan et al., 2010; Zhang et al., 2011, 2012). In the
current work, we study the effects of miR-23a expression in HOS
cells, which are distinguished from other human osteosarcoma
cells by their ability to undergo a bone cell lineage differentiation
program (Siggelkow et al., 1998; Hassan et al., 2010).
2. Materials and Methods
2.1. Cell Culture and Bone Differentiation
All cell lines were obtained from ATCC. The cells were grown
in DMEMmedia with 10% fetal bovine serum and supplemented
with 1% penicillin and streptomycin. HOS cells were grown to got
100% confluence, followed by differentiation at 7–9 days induced
by bone inducing agents, that include L-ascorbic acid 50 ug/ml
and beta-glycerophosphate 5mM (Hassan et al., 2006). Cells were
harvested at indicated times for mRNA and protein extraction or
fixed with 10% neutral-buffered formalin (NBF) for detection of
calcium deposits by Alizarin Red staining.
2.2. RNA Analyses
Total RNA was isolated using Trizol reagent (Invitrogen),
treated with DNase I (Ambion) and reverse transcribed using
“iScript Reverse Transcription Supermix for RT-qPCR” (BIO-
RAD). GJA1 and COL1A1 gene expression qRT-PCR were
performed using the TaqMan Gene Expression Assays (ABI/ Life
Technologies). mRNA levels were normalized to housekeeping
gene ACTB. miRNA-23a was quantified in triplicate using
the TaqMan MicroRNA Assay (ABI/ life technologies) and
normalized to U6. mRNA levels were assayed for relative
expression using procedure described in Livak and Schmittgen
(2001).
2.3. Illumina Expression Arrays
HOS cells were transfected with human hsa-miR-23a, or negative
control mimic (Thermo Scientific) for 72 h. 150 ng of each
RNA was amplified and labeled using the “Illumina TotalPrep
RNA Amplification kit" (LifeTechnologies). The biotin-labeled
cRNAs were quantitated spectrophotometrically and 750 ng was
hybridized to Illumina HumanRef-8v3 Expression BeadChip
microarrays (Illumina, San Diego, CA). BeadChips were scanned
in an Illumina Scanner. The data has been deposited in the
GEO database under accession number. One SuperSeries record
GSE68014; Two regular Series records: GSE68012 andGSE68012.
2.4. Protein Immunoblot Analyses
Whole cell lysates from transfected HOS cells were prepared
using RIPA buffer. Proteins were analyzed by SDS PAGE,
transferred to nitrocellulose membranes and probed with GJA1
antibody (ab11370 Abcam). Western Blots were quantified by
densitometry.
2.5. Luciferase Reporter Assay
HOS cells were co-transfected in 24 well-plates using
Lipofectamine 2000 (Invitrogen) with 20 nM miR-23a mimic
or control miRNA mimic and 100 ng of psiCHECK2- 3UTR
(Promega) vector containing the GJA1-3UTR cloned into
the multiple cloning site of Renilla luciferase. After 48 h of
transfection luciferase activity was measured using the Dual
Luciferase Assay System (Promega). The experiment was
performed in triplicate. Results were normalized to those
obtained in cells transfected with an empty vector. Data were
normalized to Firefly luciferase and results from 3 independent
experiments were compared. GJA1 sequences were cloned into
psiCHECK-2 by annealing complementary oligomers matching
each GJA1 sequence with overhanging ends complementary to
the XhoI and NotI sites of psiCHECK-2.
2.6. siGJA1 Transfection Assay
HOS cells were differentiated as described above. One day
after induction of differentiation, cells were transfected using
Lipofectamine RNAiMAX Reagent (Invitrogen) with ON-
TARGETplus-siGJA1-pool, siGJA1-05, siGJA1-06 (Thermo
Scientific L-011042-00-0005) at a final concentration of 100
pmol. After 72 h transfection, on differentiation day 4, the cells
were harvested for mRNA, protein assays, and ALP activity assay
or fixed with 10% NBF for detection of calcium deposits by
Alizarin Red Staining.
2.7. ALP assay in siGJA1-Transfected HOS Cells
Alkaline phosphatase activity was determined in HOS cell
lysates using the colorimetric Alkaline Phosphatase Assay
Kit (Abcam, Cat No: ab83369). The kit uses p-nitrophenyl
phosphate as a phosphatase substrate, which turns yellow when
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dephosphorylated by alkaline phosphatase. The absorbance at
405 nm was measured using a multi well plate reader (550
Microplate Reader; Bio-Rad Laboratories). Each assay condition
was carried out in triplicate. Cell lysates were analyzed for
protein content using the Bio-Rad DC Protein Assay (Bio-Rad
Laboratories), and alkaline phosphatase activity was normalized
for total protein concentration.
2.8. Alizarin Red Staining in siGJA1 Transfected
HOS Cells
HOS cells were fixed with 10%NBF*(10%Formalin solution,
neutral buffered, SIGMA HT501128-4L) on differentiation day
4 with GJA1 silencing 72 h, followed by “Alizarin Red S
Staining” (SIGMA A5533-25G) using NovaUltra Special Stain
Kits protocol. The red staining is indicative of calcium deposits.
2.9. Data Analysis
All statistical analyses were carried out using the R statistical
environment version 3.0. Microarray data were analyzed using
limma package (Smyth, 2005). Data from GEO were obtained
using the GEOquery package (Davis and Meltzer, 2007).
3. Results
3.1. Induction of Differentiation in Osteosarcoma
Cells
To confirm that HOS cells are amendable to bone differentiation
induction (Siggelkow et al., 1998), we treated these cells with
L-ascorbic acid, which induces the formation of collagenous
extracellular matrix and brings an osteoblast-specific gene
expression program in osteogenic lineage cells (Franceschi et al.,
1994). We then monitored HOS cell culture for the presence of
calcium deposits, which serve as amarker of bonemineralization,
via Alizarin Red staining. Our results indicate that HOS
cells undergo osteoblast-like differentiation upon stimulation
with L-ascorbic acid. HOS cells exhibit intense Alizarin Red
staining on day 7 post differentiation induction (Figure 1). We
confirmed this result by monitoring the expression of collagen
Ia1 (COL1A1)—a gene marker of bone differentiation (Figure 2).
We have observed a two-fold increase in COL1A1 mRNA levels
between the initial and terminal differentiation time-points.
3.2. miR-23a Targets Genes Involved in Bone
Differentiation
To study the effect of miR-23a on the gene expression
program in osteosarcoma, we set out to identify genes that are
transcriptionally repressed by miR-23a in HOS cells. To that
end, we first transfected HOS cells with a miR-23a mimic and
compared their gene expression profile with mock-transfected
cells using Illumina microarrays. Our analysis shows that 1530
genes (see Supplemental Table 1) are down-regulated in miR-
23a transfected cells vs. mock-transfected cells. These genes are
significantly enriched for predicted (Lewis et al., 2005) miR-
23a targets (262 overlapping genes (see Supplemental Table 2);
Poverlap = 4.96× 10
−46).
Having established the on-target effects of miR-23a over-
expression in HOS cells, we next asked if the genes affected
FIGURE 1 | Alizarin red staining of HOS cells. (A) Alizarin red staining of
HOS cells during the differentiation time course. Red staining is indicative of
calcium deposits. (B) Untreated cells.
FIGURE 2 | COL1A1 expression in HOS differentiation time course.
Relative expression levels (assayed with qPCR) of COL1A1 during HOS
differentiation time course. Expression levels are normalized to the initial time
point. Error bars represent standard deviation.
by miR-23a overlap significantly with genes that change in
expression during HOS differentiation. Given miR-23a’s role as
a dampener of bone differentiation gene expression program
(Hassan et al., 2010), we focused on genes that are up-
regulated during the HOS differentiation time course. To that
end, we compared mRNA expression levels in HOS cells
prior to differentiation induction with that of HOS cells that
display phenotypic properties of bone cells post differentiation
induction usingmicroarrays in triplicate. Our analysis shows that
3065 genes (see Supplemental Table 3) increase in expression
during HOS cell differentiation. Of those, 466 genes (see
Supplemental Table 4) are down-regulated upon miR-23a
transfection (Poverlap = 1.21 × 10
−10). To identify genes of
interest that are under miR-23a control and are relevant to HOS
cell differentiation, we identified 77 genes (see Supplemental
Table 5) that meet the following criteria: (i) are computationally
predicted miR-23a targets; (ii) are down- regulated on miR-23a
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over-expression and; (iii) are up-regulated during HOS cell
differentiation time course.
Transcription factor binding site enrichment analysis (Loots
et al., 2002) reveals that more than one-half of the 77 genes
contain an SP1 transcription factor motif within 2 kb of their
transcription start site [42 genes (see Supplemental Table 6);
Penrichment = 1 × 10
−23]. These results suggest that over-
expression of miR-23a interferes with the bone differentiation
program by counteracting the action of osteoblast lineage
inducing transcription factors binding to the SP1 motif. The
SP1 transcription factor family include osterix (SP7), a bone
lineage specific factor required for osteoblast differentiation
and bone formation (Nakashima et al., 2002). These results
suggest that over-expression of miR-23a interferes with the bone
differentiation program by counteracting the action of osteoblast
lineage inducing transcription factor SP1. In order to narrow
down the list of likely miR-23a targets that are involved in
bone differentiation we looked for gene signature enrichments,
as curated in Molecular Signatures Database (Subramanian
et al., 2005), among the 42 high-quality miR23a down-regulated
genes with an upstream SP1 binding site. The top-enriched
signature is that of genes up-regulated upon EZH2 knock-
down in prostate cancer cells (Nuytten et al., 2008) (Table 1;
Poverlap = 3.61× 10
−9). EZH2, the catalytic subunit of the PRC2
repressive complex, is commonly associated with silencing of
pro-differentiation genes (Simon and Lange, 2008), a function
analogous with that of miR-23a in bone differentiation. This
observation is particularly interesting as prostate metastatic
tumors are often osteoblastic (Logothetis and Lin, 2005) and
phosphorylation of EZH2 by CDK1 is critical for osteogenic
differentiation of human bone-marrow-derived mesenchymal
cells (Wei et al., 2011).
3.3. GJA1 is a Major Target of miR-23a
In order to identify a specific miR-23a target related to bone
differentiation, we examined the gene list in Table 1 for genes
involved in sensing extracellular environment and intercellular
communication, which are essential in bone formation that are
also present in the aforementioned gene signatures. Expert-based
examination of the gene list, through the use of manual curation
and gene ontology functionality related to bone differentiation,
led a gene whose product is connexin(Cx)-43 (also known as
TABLE 1 | miR-23a Target Genes Relevant to HOS Differentiation.
Gene symbol Gene name
CAB39 Calcium binding protein 39
CLDN12 Claudin 12
DCBLD2 Discoidin, CUB and LCCL domain containing 2
FAM46A Family with sequence similarity 46, member A
GJA1 Gap junction protein, alpha 1, 43kDa (connexin 43)
IRF1 Interferon regulatory factor 1
MARCKS Myristoylated alanine-rich protein kinase C substrate
RAB8B RAB8B, member RAS oncogene family
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3
UBL3 Ubiquitin-like 3
GJA1). GJA1 is a member of the gap junction family and is the
most abundant gap junction expressed in bone (Loiselle et al.,
2013), where it facilitates response to extracellular mechanical
(Jiang et al., 2007), pharmacologic and hormonal stimuli (Plotkin
and Bellido, 2013) and is required for signal transduction among
bone lineage cells (Civitelli, 2008). Crucially, GJA1 is essential for
osteoblast differentiation in humans and animals in vivo (Stains
and Civitelli, 2005a).
We verified that the miR-23a binding site is well-conserved
in 3′UTR of the GJA1 gene (Lewis et al., 2005; Friedman et al.,
2009).We next sought to verify miR23a:GJA1 interaction in vitro.
To that end we carried out a reporter assay where the 3’UTR
of GJA1 was cloned into the 3′UTR of a luciferase gene. We
find that miR-23a significantly reduces luciferase GJA1 reporter
activity (Figure 3). These results confirm that GJA1 is a bona fide
miR-23a target.
We then set out to elucidate the expression pattern of GJA1
during osteoblast cell differentiation. To that end, we identified,
in Gene Expression Omnibus (GEO) (Barrett et al., 2013), a
dataset used in two recently published studies (Nabavi et al., 2012;
Pustylnik et al., 2013) that assayed gene expression in mouse
MC3T3-E1 osteoblast cells following differentiation induction by
L-ascorbic acid. Neither study explicitly addressed gap junction
expression in osteoblast differentiation. Our analysis of the data
deposited inGEO shows thatGJA1 expression increases over 500-
fold (6-probe average; P < 1.0× 10−6) in mouse osteoblast cells
following differentiation.
Next, we asked whether GJA1 expression levels increase
during HOS cell differentiation and how this expression pattern
may be related to miR-23a expression. To that end, we induced
differentiation in HOS cells and analyzed mRNA expression with
quantitative (q)PCR. Our results show (Figure 4) thatGJA1 levels
increase as HOS cells begin to display phenotypical hallmarks
of osteblast cells. GJA1 levels reach their maximum on day 7
post differentiation induction, at which point HOS cells display
FIGURE 3 | Effect of miR-23a mimic on GJA1 3′ UTR luciferase activity.
HOS cells were co-transfected with either miR-23a mimic or control miRNA
mimic and psiCHECK2- 3UTR vector containing the GJA1-3UTR of Renilla
luciferase. Data were normalized to Firefly luciferase activity and cells
transfected with empty psiCHECK-2 control vectors. Error bars represent
standard deviation of technical repeat experiments (n = 3). P-value calculated
by Student’s t-test.
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the phenotypic properties of bone differentiation (Figure 1) and
COL1A1 levels have reached their peak (Figure 2). Importantly,
miR-23a levels are inversely related to GJA1 expression: reaching
minimum, when GJA1 levels are at their peak and Alizarin red
staining is at its maximum; then increasing gradually past day 4
when GJA1 levels off and begins to decrease.
3.4. Knock-down of GJA1 Delays HOS Cell
Differentiation
We next examined the relationship between GJA1 expression
and HOS cell differentiation (Figure 5). To that end, we
FIGURE 4 | Relative expression of GJA1 and miR-23a during HOS cell
differentiation time course. HOS cells were induced to differentiate and
mRNA aliquots were isolated at selected time points (x-axis). Relative
expression of GJA1 and miR-23a were normalized, separately, to their basal
levels (Day 0). Error bars represent standard deviation due to technical repeats
(n = 3).
once again induced HOS cell differentiation, but this time
transfecting HOS cells with GJA1 siRNA constructs 24 h
after differentiation induction. First, we examined the GJA1
knock-down effect on differentiation qualitatively via Alizarin
Red staining (Figure 5A). As shown in Figure 5A, cells that
were transfected with GJA1 siRNA produced less extracellular
calcium deposits (as evidence by stain intensity) compared to
either to either of the negative controls. Lastly, we sought
to quantitatively measure the effect of GJA1 knock-down on
HOS cell differentiation. To that end we measured alkaline
phosphatase (ALP) activity in these cells after differentiation
induction and transfection with either GJA1 siRNA or negative
controls. As shown in Figure 5B, there is a more than a two-
fold reduction in ALP activity in HOS cells where GJA1 is
knocked-down in siRNA. Importantly, GJA1 siRNA transfection
led to decreased GJA1 protein levels in both of these experiments
(Figure 5). Together, these results demonstrate that reduction
of GJA1 expression prevents HOS cells from displaying matrix
calcification phenotype and ALP activity that is associated with
osteoblast cells (Figure 5).
4. Discussion
A number of recent studies have identified miRNAs that are
differentially expressed between normal bone and osteosarcoma
(see recent summaries in Miao et al., 2013 and Zhou et al.,
2013). Importantly, miR-23a has been shown to control bone
differentiation (Hassan et al., 2010; Zhang et al., 2011, 2012).
However, it is not clear what role, if any, miR-23a has within
the realm of osteosarcoma. Studies that focused on the function
of miR-23a in bone differentiation have been restricted to the
examination of miR-23a and expression of transcription factors
that are paramount to bone biology such as RUNX2 (Zhang
FIGURE 5 | Effect of GJA1 knock-down on HOS cell differentiation.
HOS cells were induced to differentiate and were then transfected with
either: (i) a scrambled siRNA negative control, or (ii) empty buffer negative
control, or (iii) a pool of GJA1 siRNA constructs, or (iv) a single GJA1
siRNA construct number 6. 72 h after transfection cells were either (A)
stained with Alizarin Red, or (B) subjected to measurement of alkaline
phosphatase (ALP) activity. In both cases, an aliquot of cells was used to
measure to GJA1 protein concentration via Western blot (bottom panels
images). Error bars represent standard error from the mean from three
replicates.
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et al., 2011, 2012) and/or SATB2 (Hassan et al., 2010), which
were chosen a priori. We find that miR-23a acts to inhibit
differentiation, at least in part, by blocking the expression of
connexin 43 (GJA1) a key protein for of cell-cell communication
and osteoblast differentiation.
In this study we examined the relationships between miR-
23a and bone differentiation within the context of osteosarcoma.
Previous studies demonstrated the relationship between miR-23a
and transcription factors that are central to bone differentiation
program (Hassan et al., 2010; Zhang et al., 2012). Separately,
Inose et al. (2009) have shown that bone differentiation is
negatively impacted in mice by miR-206-mediated silencing
of GJA1. We could not detect miR-206 expression in HOS
nor human osteoblast cells (data not shown). This points to
redundant pathways that fine-tune GJA1 expression during bone
differentiation.
Loss of gap junctional communication delays osteoblast
differentiation and reduces the ability of these cells to form
mineralized extracellular matrix (Lecanda et al., 1998; Schiller
et al., 2001). A clue as to how this effect arises came from
an observation that loss of GJA1 function is accompanied by
diminished extracellular-signal-regulated kinase (ERK) activity
(Stains and Civitelli, 2005b). In the proposed mechanism, a GJA1
gap junction allows for passage of a 2nd messenger activating
ERK/PI3K signaling cascades that would in turn recruit
transactivator SP1 to promoter regions of genes associated with
the osteoblastic gene expression program, such as osteocalcin
and COLIA1 (Stains et al., 2003; Stains and Civitelli, 2005b).
The loss of GJA1 gap junctions diminishes ERK activity resulting
in preferential recruitment of SP3 repressor to osteocalcin and
COLIA1 gene promoters (Stains et al., 2003; Stains and Civitelli,
2005b). Here, we show that miR-23a gene targets in HOS
cells are enriched for SP1 binding site within 2kb of their
transcription start site, which suggests thatmiR-23amay function
by counteracting the effects of the SP1 family of transcription
factors.
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